Claire Petry

464 total citations
14 papers, 342 citations indexed

About

Claire Petry is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Claire Petry has authored 14 papers receiving a total of 342 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 6 papers in Genetics and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Claire Petry's work include Hemophilia Treatment and Research (8 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (6 papers) and Platelet Disorders and Treatments (5 papers). Claire Petry is often cited by papers focused on Hemophilia Treatment and Research (8 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (6 papers) and Platelet Disorders and Treatments (5 papers). Claire Petry collaborates with scholars based in Switzerland, United States and Germany. Claire Petry's co-authors include Christophe Schmitt, François Mercier, Nicolas Frey, Gallia G. Levy, Ludwig Kappos, Andreas Guenther, Stephen L. Hauser, Heidemarie Kletzl, Sylvie Retout and Fabian Model and has published in prestigious journals such as Blood, Neurology and Annals of the Rheumatic Diseases.

In The Last Decade

Claire Petry

14 papers receiving 339 citations

Peers

Claire Petry

HEMAT

GENET

PFM

ONCOL

IMMUN

Cecilia Isaksson Sweden

M Kazmi United Kingdom

Sujaatha Narayanan Canada

H. Yesid Estupiñán Colombia

John‐Philip Lawo Germany

Denis A. Fedorenko Russia

María García‐Álvarez Spain

Anna Ruskova New Zealand

M. T. Vatutin Ukraine

E. Alyea United States

Cecilia Isaksson Sweden

Claire Petry

238 ×1.3

HEMAT

56 ×0.6

GENET

119 ×1.4

PFM

94 ×1.5

ONCOL

62 ×1.0

IMMUN

Citations per year, relative to Claire Petry Claire Petry (= 1×) peers Cecilia Isaksson

Countries citing papers authored by Claire Petry

Since Specialization

Citations

This map shows the geographic impact of Claire Petry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claire Petry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claire Petry more than expected).

Fields of papers citing papers by Claire Petry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claire Petry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claire Petry. The network helps show where Claire Petry may publish in the future.

Co-authorship network of co-authors of Claire Petry

This figure shows the co-authorship network connecting the top 25 collaborators of Claire Petry. A scholar is included among the top collaborators of Claire Petry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claire Petry. Claire Petry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Hauser, Stephen L., Amit Bar‐Or, Martin S. Weber, et al.. (2023). Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation. 10(2). 28 indexed citations

Kiialainen, Anna, Joanne I. Adamkewicz, Claire Petry, et al.. (2023). Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks. Research and Practice in Thrombosis and Haemostasis. 8(1). 102306–102306. 4 indexed citations

Schmitt, Christophe, Maria Elisa Mancuso, Tiffany Chang, et al.. (2022). Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A. Haemophilia. 29(1). 90–99. 13 indexed citations

Schmitt, Christophe, Thomas Emrich, Sammy Chebon, et al.. (2021). Low immunogenicity of emicizumab in persons with haemophilia A. Haemophilia. 27(6). 984–992. 46 indexed citations

Jönsson, Fredrik, Christophe Schmitt, Claire Petry, et al.. (2021). Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII. Clinical Pharmacokinetics. 60(7). 931–941. 15 indexed citations

Italiano, Antoîne, Wilson H. Miller, Jean‐Yves Blay, et al.. (2021). Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors. Investigational New Drugs. 39(6). 1587–1597. 27 indexed citations

Yoneyama, Koichiro, Christophe Schmitt, Tiffany Chang, et al.. (2021). A Model‐Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A. The Journal of Clinical Pharmacology. 62(2). 232–244. 9 indexed citations

Retout, Sylvie, Christophe Schmitt, Claire Petry, François Mercier, & Nicolas Frey. (2020). Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A. Clinical Pharmacokinetics. 59(12). 1611–1625. 31 indexed citations

Schmitt, Christophe, Joanne I. Adamkewicz, Jin Xu, et al.. (2020). Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study. Thrombosis and Haemostasis. 121(3). 351–360. 69 indexed citations

10.

Gibiansky, Ekaterina, Claire Petry, François Mercier, et al.. (2020). Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. British Journal of Clinical Pharmacology. 87(6). 2511–2520. 60 indexed citations

11.

Jamois, Candice, Doreen Anders, Benjamin M. Beckermann, et al.. (2020). Contribution of Idasanutlin Exposure to Safety, Pharmacodynamics and Clinical Response of Patients with Acute Myeloid Leukemia Treated with Idasanutlin + Cytarabine in Phase I and III Studies. Blood. 136(Supplement 1). 7–8. 2 indexed citations

12.

Li, Haiyan, Weijiang Zhang, Claire Petry, et al.. (2020). Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. 10(1). 30–38. 9 indexed citations

13.

Kletzl, Heidemarie, Ekaterina Gibiansky, Claire Petry, et al.. (2019). Pharmacokinetics, Pharmacodynamics and Exposure-Response Analyses of Ocrelizumab in Patients With Multiple Sclerosis (N4.001). Neurology. 92(15_supplement). 12 indexed citations

14.

Sostelly, Alexandre, Guillemette Duchâteau-Nguyen, Claire Petry, et al.. (2019). OP0224 RESULTS OF A PHASE 2 STUDY OF RG6125, AN ANTI-CADHERIN-11 MONOCLONAL ANTIBODY, IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO ANTI-TNFALPHA THERAPY. Annals of the Rheumatic Diseases. 78. 189–189. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact